Today, the American Diabetes Association® (ADA) announced the awardees of the 2025 Pathway to Stop Diabetes® (Pathway) grants ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on w ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

GLP-1 is a hormone made naturally in the gut. It plays a big role in managing blood sugar and appetite while releasing ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...

Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...